Open Access

Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel

  • Authors:
    • Hugo Mendieta Zerón
    • José Meneses Calderón
    • Leopoldo Paniagua Coria
    • Jazmín Meneses Figueroa
    • María José Vargas Contreras
    • Humberto Luis Vives Aceves
    • Fernando Manuel Carranza Salazar
    • David Californias Hernández
    • Erika Miraflores Vidaurri
    • Alberto Carrillo González
    • José Anaya Herrera
  • View Affiliations

  • Published online on: March 4, 2021     https://doi.org/10.3892/wasj.2021.94
  • Article Number: 23
  • Copyright: © Mendieta Zerón et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The use of nitazoxanide has previously yielded successful results in vitro against the coronavirus. The aim of the present study was to examine the efficacy of the use of nitazoxanide at an early stage among healthcare workers exhibiting symptoms of COVID‑19. This was a prospective study carried out in 2020. Healthcare personnel who presented with COVID‑19 symptoms, in different 3 hospitals were invited to take Paramix (nitazoxanide), 500 mg orally, every 6 h for 2 days and then 500 mg twice a day for 4 days. To compare the hospitalization percentage, a group of healthcare workers with a respiratory viral infection without COVID‑19 criteria were also followed‑up. Over a period of 3 months, 150 healthcare workers (111 women and 39 men) presented respiratory symptoms with COVID‑19 criteria (mean age, 36±10.6 years; range, 18‑68 years). Only one female medical doctor, one nurse and one male from the auxiliary services had to be hospitalized and one death was registered It was thus concluded that nitazoxanide yielded successful results in vitro against previous coronavirus and may prove to be useful against SARS‑CoV‑2 as an early intervention to avoid complications, decreasing the expected number of hospitalizations among infected healthcare workers.
View References

Related Articles

Journal Cover

May-June 2021
Volume 3 Issue 3

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Mendieta Zerón H, Meneses Calderón J, Paniagua Coria L, Meneses Figueroa J, Vargas Contreras M, Vives Aceves H, Carranza Salazar F, Californias Hernández D, Miraflores Vidaurri E, Carrillo González A, Carrillo González A, et al: Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel. World Acad Sci J 3: 23, 2021.
APA
Mendieta Zerón, H., Meneses Calderón, J., Paniagua Coria, L., Meneses Figueroa, J., Vargas Contreras, M., Vives Aceves, H. ... Anaya Herrera, J. (2021). Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel. World Academy of Sciences Journal, 3, 23. https://doi.org/10.3892/wasj.2021.94
MLA
Mendieta Zerón, H., Meneses Calderón, J., Paniagua Coria, L., Meneses Figueroa, J., Vargas Contreras, M., Vives Aceves, H., Carranza Salazar, F., Californias Hernández, D., Miraflores Vidaurri, E., Carrillo González, A., Anaya Herrera, J."Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel". World Academy of Sciences Journal 3.3 (2021): 23.
Chicago
Mendieta Zerón, H., Meneses Calderón, J., Paniagua Coria, L., Meneses Figueroa, J., Vargas Contreras, M., Vives Aceves, H., Carranza Salazar, F., Californias Hernández, D., Miraflores Vidaurri, E., Carrillo González, A., Anaya Herrera, J."Nitazoxanide as an early treatment to reduce the intensity of COVID‑19 outbreaks among health personnel". World Academy of Sciences Journal 3, no. 3 (2021): 23. https://doi.org/10.3892/wasj.2021.94